NGM Biopharmaceuticals (NYSE:NGM) major shareholder Group L. P. Column bought 34,377 shares of the stock in a transaction dated Friday, June 21st. The shares were bought at an average cost of $13.90 per share, with a total value of $477,840.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Shares of NGM opened at $13.80 on Monday. NGM Biopharmaceuticals has a 12-month low of $12.00 and a 12-month high of $18.75.

NGM Biopharmaceuticals (NYSE:NGM) last issued its earnings results on Thursday, May 16th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.90). The firm had revenue of $25.55 million for the quarter.

A number of analysts have recently issued reports on NGM shares. Citigroup started coverage on shares of NGM Biopharmaceuticals in a research note on Monday, April 29th. They set a “buy” rating and a $29.00 target price for the company. Goldman Sachs Group started coverage on shares of NGM Biopharmaceuticals in a research note on Monday, April 29th. They set a “buy” rating and a $22.00 target price for the company. Finally, Cowen started coverage on shares of NGM Biopharmaceuticals in a research note on Monday, April 29th. They set an “outperform” rating and a $25.00 target price for the company.

NGM Biopharmaceuticals Company Profile

NGM Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include NGM282, an engineered variant of the FGF19 human hormone in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that selectively activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b early proof-of-concept clinical trials for use in the treatment of type 2 diabetes and NASH; and NGM386 and NGM395, which are engineered variants of the GDF15 human hormone for use in the treatment of obesity.

Featured Story: The role of implied volatility with call option volume

Insider Buying and Selling by Quarter for NGM Biopharmaceuticals (NYSE:NGM)

Receive News & Ratings for NGM Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NGM Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.